Morningstar® Stock Report™

Carl Zeiss Meditec AG AFX

Gewinnmarge (% des Umsatzes)
20192020202120222023
Ertrag100,00%100,00%100,00%100,00%100,00%
Betriebskosten43,00%44,17%41,27%40,74%42,29%
Bruttogewinn57,00%55,83%58,73%59,26%57,71%
Vertriebsgemeinkosten26,99%26,15%22,10%23,02%24,13%
Forschung und Entwicklung11,88%16,38%14,09%15,31%16,72%
Umsatzrendite18,14%13,30%22,69%20,86%16,66%
Net Int, Inc and Other33,89%26,68%43,28%42,06%36,41%
EBIT Marge15,75%13,38%20,59%21,20%19,75%
Ertragskraft
20192020202120222023
Steuersatz4,75%4,14%6,17%5,65%5,77%
Nettomarge10,95%9,16%14,35%15,45%13,90%
Gesamtkapitalrendite8,676,0710,7211,269,92
Financial Leverage1,451,411,441,401,40
Eigenkapitalsrendite11,878,6515,2916,0013,91